New shot aims to stop the maddening itch of prurigo nodularis

NCT ID NCT06554509

Recruiting now Symptom relief Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an injection called SHR-1819 to see if it can safely reduce the intense itching caused by prurigo nodularis, a chronic skin condition with hard, itchy bumps. About 423 adults will receive either the drug or a placebo, and researchers will track how much their worst itch improves over 16 to 24 weeks. The goal is to find a new treatment option for people who suffer from this distressing itch.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRURIGO NODULARIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prurigo nodularis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRURIGO NODULARIS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Peking University People's Hospital
RECRUITING

Beijing, Beijing Municipality, 100032, China

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact